HLA Antigens Dw4 and Dw14 in Rheumatoid Arthritis

Total Page:16

File Type:pdf, Size:1020Kb

HLA Antigens Dw4 and Dw14 in Rheumatoid Arthritis Ann Rheum Dis: first published as 10.1136/ard.46.6.492 on 1 June 1987. Downloaded from 492 Correspondence absence of another cause such as renal failure or liver Table 1 Phenotvpes of DW4 or Dw/4 positive patients, or disease), as has been previously suggested; however, it can patients positive for both also be associated with an acute phase reaction, and this should be borne in mind when interpreting the significance Patient.s witliout Patients with of VWF measurements. toxch- effects toxic eff cts ( =23) (0t =61) MRC Clinical Research Centre. J L GORDON Dw4/x or -, 6 13 Harrow. B E POTTINGER DwI4/x or - 2 6 Middlesex P woo Dw4/w14 5 () H6pital Henri Mondor. J ROSENBAUM "D typing missed in one patient. Paris .x means any other HLA-D specificitNr found. West Middlesex Hospital. C M BLACK 'In DR typing only DR4 was found. Isleworth. Middlesex group. which was more heterogeneous as to the American References Rheumatism Association criteria.-' Although we emphasised the differences in Dw4 and I Jaffc E A. Hoyer L W. Nachman R L. Synthesis of von Willebrand antihemophilic factor antigen by cultured human Dwl frequencies between the groups. the higher Dw14 cndothelial cells. Proc Natl Acad Sci USA 1973: 71: 1906-9. prevalence in the RA controls with classical RA was 2 Sakariassen K S. Bolhuis P A. Sixma J J. Human blood platelet disregarded in the discussion. adhcrence to artery subendothelium is mcdiated by factor VlIl- Recently, Dr Nepom and colleagues identified HLA- von Willebrand factor bound to the subendothelium. Nature Dw4/w14 heterozygosity by allele specific oligonucleotide 1979; 279: 636-8. probes in five out of seven phenotypically DR4 homozy- 3 dc Groot P G. Gonsalves M D. Locsberg C. van Buul- gous (RA) patients who were found among 45 selected Wortelbocr M F. van Aken W G. van Mourik J A. Thrombin- Caucasian RA and seropositive induced reease of von Willebrand factor from endothelial cells patients with classical is mcdiated by phospholipid methylation. Prostacyclin synthesis disease. They proposed that their report was the first to is independent of phospholipid methylation. J Biol Chesn 1984; describe high Dwl4 in adult RA and suggested that thecopyright. 259: 13329-33. Dw14 allele may play an important part in susceptibility to 4 Angles-Cano E. Sultan Y. Clauvel J P. Predisposing factors to RA. thrombosis in systemic lupus erythematosus. Possible relation We have now re-evaluated our series with regard to to endothelial cell damage. J Lab Cliti Med 1979; 94: 312-23. Dw4/Dw14 status. The table shows the phenotypes of Dw4 5 Kahaleh M B. Osborn 1. LeRov E C. Increased factor VIII/von or Dwl4 positive patients. or patients positive for both, in Willcbrand factor antigen and von Willebrand factor activity in each group. The five Dw4/w14 heterozygotes in the group scieroderma and in Ravnaud's phenomenon. Atiti Itnteris Med 1981: 94: 482-4. with classical RA without gold toxicity was significantly 6 Nusinow S. Fcderici A B. Zimmerman T S. Curd J G. more than the expected number of 2()9 calculated from thehttp://ard.bmj.com/ Incrcased von Wiilebrand factor antigen in the plasma of phenotype frequencies (X-=4(05. p<0(05). Instead, none patients with vasculitis. Arthritis Rheutoi 1984; 27: 140)5-11). of the patients with gold toxicity was Dw4/w14 hetero- 7 Lee P. Norman C S. Sukenik S. Alderdiec C A. The clinicial zygous. Our results obtained with cellular HLA-D typing significaince of coagulation abnormalities in systemic scierosis thus agree with those of Dr Nepom and colleagues (scleroderma). J Rheutnatol 1985; 12: 514-7. concerning classical RA. Although the Dw4 and Dw14 8 Glueck H 1. Kant K S. Weiss M A. Pollak V E. Miller M A. genes both may be associated with disease susceptibilitv Coots M. Thrombosis in systemic lupus erythematosus. Rela- tion to the presencc of circulating anticoagulants. Arc/h Ititerus (gene). their effect on the clinical picture of RA max be even stronger. Med 1985; 145: 1389-95. on September 28, 2021 by guest. Protected 9 Kelly D. Tuddenham E G D. Summerfield J A. The effect of an acute phase reaction and BCG inoculation on ftactor Vil in the Department of Medicine. NIARKKLI HAKALA guinea pig. T/srornh Res 1985; 40: 445- 1. Paivarinne Hospital. Muhos. Finland National Public JORMA ILONEN Health Institute. HLA antigens Dw4 and Dw14 in Oulu, Finland Department of ANJA TIILIKAINEN rheumatoid arthritis Medical Microbiology. University of Oulu, SIR. In a recent study in the Annals of Rheumatic Diseases Oulu, Finland we assayed the differences in HLA system of 62 patients with rheumatoid arthritis (RA) with various toxic effects of References gold salts and 23 RA controls without gold toxicity.' The I Hakala M. vain Assendelft A H W. Iloncn J. Jalasa S. findings included higher Dw4 and Dwl4 and lower Dwl Tiilikainen A. Associiation of diffcrent HLA aintigcns with incidences in the controls with classical rheumatoid vairious toxic cffects of gold sallts in rhcumaitoid airthritis. Asiss arthritis (RA) when compared with the gold toxicity Rl/eun Dixs 1986; 45: 177-82. Ann Rheum Dis: first published as 10.1136/ard.46.6.492 on 1 June 1987. Downloaded from Correspondence 493 2 Ropes M W. Bennett G A. Cobb S. Jacox R. Jessar R A. 6 Auscher C. Pasquier C. Mercier N. Delbarre F. Oxidation of Revision of diagnostic criteria for rheumatoid arthritis. Bull pyrazolo (3.4-d) pyrimidine in a xanthinuric man. Isr J Med Sci Rheu,n Dis 1958: 9: 175-6. 1973: 9: 3. 3 Nepom G T. Seyftied C E. Holbeck S L. Wilske K R. 7 Elion G B. Benezra F M. Caneilas 1. Carrington L 0. Hitchings Nepom B S. Identification of HLA-DwI4 genes in DR4+ G H. Effects of xanthine oxidase inhibitors on purine meta- rheumatoid arthritis. Lancet 1986: ii: 1(0)2-5. bolism. Isr J Clzetn 1968; 6: 787-96. 8 Rundles R W. Metz E N. Silberman H R. Allopurinol in the treatment of gout. Aiiii ltiter,i Med 1966: 64: 229-58. 9 Delbarre F. Amor B. Auscher C. De Gery A. Treatment of gout with allopurinol: a studv of 1t)6 cases. Ann,l Rheutn Dis Alternatives to allopurinol 1966: 25: 627-33. 10 Rundles R W. Metabolic effects of allopurinol and In their letter to the Annals Kelsey et al state that alloxanthine. Atiti Rheu,n Dis 1966: 25: 615-2). SIR, 11 Lockard 0 Jr, Harmon C. Nolph K. Irvin W. Allergic reaction there is 'no available alternative to allopurinol with its to allopurinol with cross-reactiyity to oxypurinol. Ann Intern unique mode of action'.' There are at least two alter- Med 1976; 85: 333-5. natives2; tisopurine (IH-pyrazolo[3,4-d]pyrimidine-4- thiol (CSH4N4S)) and oxypurinol (lH-pyrazolo[3,4-d] pyrimidine-4.6-diol(C,H4N402)). Neither are available in the United Kingdom. In the treatment of gout, tisopurine has been shown to reduce effectively both the plasma and urinary uric acid Hyper-responsiveness to EBV levels of hyperexcretors, but plasma levels only of normal in ankylosing spondylitis excretors. These effects were shown without a concom- itant increase in urinary hypoxanthine and xanthine excretion.-" Tisopurine is only one tenth as active as SIR. Recently, Drs Robinson and Panayi reported a allopurinol (1H-pyrazolo[3,4-dlpyrimidin-4-ol(C,H4N40)) deficient control of in vitro Epstein-Barr virus (EBV) as a xanthine oxidase inhibitor in vitro.7 and is ineffective infection in patients with ankylosing spondylitis (AS).' in lowering uric acid levels in gout associated with a partial Under blind study control, using peripheral blood mono- deficiency of the enzyme hypoxanthine guanine phos- nuclear cells from B27+ spondylitic patients, we have copyright. phoribosyl transferase.3 5 Therefore, tisopurine reduces observed a similar hyper-responsiveness to EBV. Cultures uric acid concentrations by interfering with the early stages were set up in quadruplicate in 96-well, flat bottomed of its synthesis, thus avoiding increased blood concen- microtitre plates. Virus supernatant, obtained from a 10 trations of hypoxanthine and xanthine. There is no day culture of B95-8 marmoset cells, was titrated and evidence that there is a cross reactivity between tisopurine mononuclear cells were added to each well to give a final and allopurinol. The dose range is from 200 to 400 mg concentration of 5 x 105 cells/ml. Fig. 1 shows the daily. minimum virus concentration required to immortalise the Oxypurinol is the active metabolite of allopurinol in blood B cells of patients with either clinically active AS or http://ard.bmj.com/ vivo. Its half life is about eightfold longer than that of rheumatoid arthritis (RA). In these experiments, cells allopurinol.' Allopurinol is the more effective adminis- from 90% (9 of 10) of the spondylitic patients and 69% (11 tered orally in view of the relatively poor absorption of of 16) of the rheumatoid patients formed permanent cell oxypurinol from the gastrointestinal tract.' Although lines and the range of minimum concentrations was several patients with a history of untoward reactions to similar; the results are based on six week cultures. allopurinol have received oxypurinol without cross reac- Since we have shown previously an increased respon- tivity,"' others do cross react, and in some the reaction siveness to EBV of rheumatoid blood B cells2 we extended may have an immunological basis." the experiments further to evaluate the role of the spondylitic B cell in this observed hyper-responsiveness. on September 28, 2021 by guest. Protected Rheumatology Department, A S M JAWAD Non-T cells, negatively selected using 2-aminoethyliso- The London Hospital thiouronium bromide hydrobromide (AET) treated sheep erythrocytes, were infected with EBV supernatant at a References dilution of 1/10.
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Alternatives to Allopurinol Hyper-Responsiveness to EBV In
    Ann Rheum Dis: first published as 10.1136/ard.46.6.493-a on 1 June 1987. Downloaded from Correspondence 493 2 Ropes M W. Bennett G A. Cobb S. Jacox R. Jessar R A. 6 Auscher C. Pasquier C. Mercier N. Delbarre F. Oxidation of Revision of diagnostic criteria for rheumatoid arthritis. Bull pyrazolo (3.4-d) pyrimidine in a xanthinuric man. Isr J Med Sci Rheu,n Dis 1958: 9: 175-6. 1973: 9: 3. 3 Nepom G T. Seyftied C E. Holbeck S L. Wilske K R. 7 Elion G B. Benezra F M. Caneilas 1. Carrington L 0. Hitchings Nepom B S. Identification of HLA-DwI4 genes in DR4+ G H. Effects of xanthine oxidase inhibitors on purine meta- rheumatoid arthritis. Lancet 1986: ii: 1(0)2-5. bolism. Isr J Clzetn 1968; 6: 787-96. 8 Rundles R W. Metz E N. Silberman H R. Allopurinol in the treatment of gout. Aiiii ltiter,i Med 1966: 64: 229-58. 9 Delbarre F. Amor B. Auscher C. De Gery A. Treatment of gout with allopurinol: a studv of 1t)6 cases. Ann,l Rheutn Dis Alternatives to allopurinol 1966: 25: 627-33. 10 Rundles R W. Metabolic effects of allopurinol and In their letter to the Annals Kelsey et al state that alloxanthine. Atiti Rheu,n Dis 1966: 25: 615-2). SIR, 11 Lockard 0 Jr, Harmon C. Nolph K. Irvin W. Allergic reaction there is 'no available alternative to allopurinol with its to allopurinol with cross-reactiyity to oxypurinol. Ann Intern unique mode of action'.' There are at least two alter- Med 1976; 85: 333-5.
    [Show full text]
  • General Pharmacology
    GENERAL PHARMACOLOGY Winners of “Nobel” prize for their contribution to pharmacology Year Name Contribution 1923 Frederick Banting Discovery of insulin John McLeod 1939 Gerhard Domagk Discovery of antibacterial effects of prontosil 1945 Sir Alexander Fleming Discovery of penicillin & its purification Ernst Boris Chain Sir Howard Walter Florey 1952 Selman Abraham Waksman Discovery of streptomycin 1982 Sir John R.Vane Discovery of prostaglandins 1999 Alfred G.Gilman Discovery of G proteins & their role in signal transduction in cells Martin Rodbell 1999 Arvid Carlson Discovery that dopamine is neurotransmitter in the brain whose depletion leads to symptoms of Parkinson’s disease Drug nomenclature: i. Chemical name ii. Non-proprietary name iii. Proprietary (Brand) name Source of drugs: Natural – plant /animal derivatives Synthetic/semisynthetic Plant Part Drug obtained Pilocarpus microphyllus Leaflets Pilocarpine Atropa belladonna Atropine Datura stramonium Physostigma venenosum dried, ripe seed Physostigmine Ephedra vulgaris Ephedrine Digitalis lanata Digoxin Strychnos toxifera Curare group of drugs Chondrodendron tomentosum Cannabis indica (Marijuana) Various parts are used ∆9Tetrahydrocannabinol (THC) Bhang - the dried leaves Ganja - the dried female inflorescence Charas- is the dried resinous extract from the flowering tops & leaves Papaver somniferum, P album Poppy seed pod/ Capsule Natural opiates such as morphine, codeine, thebaine Cinchona bark Quinine Vinca rosea periwinkle plant Vinca alkaloids Podophyllum peltatum the mayapple
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 100 Ol
    US 2002O102215A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 Klaveness et al. (43) Pub. Date: Aug. 1, 2002 (54) DIAGNOSTIC/THERAPEUTICAGENTS (60) Provisional application No. 60/049.264, filed on Jun. 6, 1997. Provisional application No. 60/049,265, filed (75) Inventors: Jo Klaveness, Oslo (NO); Pal on Jun. 6, 1997. Provisional application No. 60/049, Rongved, Oslo (NO); Anders Hogset, 268, filed on Jun. 7, 1997. Oslo (NO); Helge Tolleshaug, Oslo (NO); Anne Naevestad, Oslo (NO); (30) Foreign Application Priority Data Halldis Hellebust, Oslo (NO); Lars Hoff, Oslo (NO); Alan Cuthbertson, Oct. 28, 1996 (GB)......................................... 9622.366.4 Oslo (NO); Dagfinn Lovhaug, Oslo Oct. 28, 1996 (GB). ... 96223672 (NO); Magne Solbakken, Oslo (NO) Oct. 28, 1996 (GB). 9622368.0 Jan. 15, 1997 (GB). ... 97OO699.3 Correspondence Address: Apr. 24, 1997 (GB). ... 9708265.5 BACON & THOMAS, PLLC Jun. 6, 1997 (GB). ... 9711842.6 4th Floor Jun. 6, 1997 (GB)......................................... 97.11846.7 625 Slaters Lane Alexandria, VA 22314-1176 (US) Publication Classification (73) Assignee: NYCOMED IMAGING AS (51) Int. Cl." .......................... A61K 49/00; A61K 48/00 (52) U.S. Cl. ............................................. 424/9.52; 514/44 (21) Appl. No.: 09/765,614 (22) Filed: Jan. 22, 2001 (57) ABSTRACT Related U.S. Application Data Targetable diagnostic and/or therapeutically active agents, (63) Continuation of application No. 08/960,054, filed on e.g. ultrasound contrast agents, having reporters comprising Oct. 29, 1997, now patented, which is a continuation gas-filled microbubbles stabilized by monolayers of film in-part of application No. 08/958,993, filed on Oct.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • (Indol-5-Yl)Thiazolederivatives As Xanthine Oxidase(XO)Inhibitors
    J. Chosun Natural Sci. Vol. 9, No. 3 (2016) pp. 190 − 198 http://dx.doi.org/10.13160/ricns.2016.9.3.190 Comparative Molecular Similarity Index Analysis on 2-(indol-5-yl)thiazolederivatives as Xanthine Oxidase(XO)inhibitors Santhosh Kumar Nagarajan and Thirumurthy Madhavan† Abstract Xanthine Oxidase is an enzyme, which oxidizes hypoxanthine to xanthine, and xanthine to uric acid. It is widely distributed throughout various organsincluding the liver, gut, lung, kidney, heart, brain and plasma. It is involved in gout pathogenesis. In this study, we have performed Comparative Molecular Field Analysis (CoMSIA) on a series of 2-(indol- 5-yl) thiazole derivatives as xanthine oxidase (XO) inhibitors to identify the structural variations with their inhibitory activities. Ligand based CoMSIA models were generated based on atom-by-atom matching alignment. In atom-by-atom matching, the bioactive conformation of highly active molecule 11 was generated using systematic search. Compounds were aligned using the bioactive conformation and it is used for model generation. Different CoMSIA models were generated using different alignments and the best model yielded across-validated q2 of 0.698 with five components and non-cross-validated correlation coefficient (r2) of 0.992 with Fisher value as 236.431, and an estimated standard error of 2 0.068. The predictive ability of the best CoMSIA models was found to be r pred 0.653. The study revealed the important structural features required for the biological activity of the inhibitors and could provide useful for the designing of novel and potent drugs for the inhibition of Xanthine oxidase. Keywords: Xanthine Oxidase, Gout, 3D-QSAR, CoMSIA.
    [Show full text]
  • Alternatives to Allopurinol Hyper-Responsiveness to EBV In
    Ann Rheum Dis: first published as 10.1136/ard.46.6.493-b on 1 June 1987. Downloaded from Correspondence 493 2 Ropes M W. Bennett G A. Cobb S. Jacox R. Jessar R A. 6 Auscher C. Pasquier C. Mercier N. Delbarre F. Oxidation of Revision of diagnostic criteria for rheumatoid arthritis. Bull pyrazolo (3.4-d) pyrimidine in a xanthinuric man. Isr J Med Sci Rheu,n Dis 1958: 9: 175-6. 1973: 9: 3. 3 Nepom G T. Seyftied C E. Holbeck S L. Wilske K R. 7 Elion G B. Benezra F M. Caneilas 1. Carrington L 0. Hitchings Nepom B S. Identification of HLA-DwI4 genes in DR4+ G H. Effects of xanthine oxidase inhibitors on purine meta- rheumatoid arthritis. Lancet 1986: ii: 1(0)2-5. bolism. Isr J Clzetn 1968; 6: 787-96. 8 Rundles R W. Metz E N. Silberman H R. Allopurinol in the treatment of gout. Aiiii ltiter,i Med 1966: 64: 229-58. 9 Delbarre F. Amor B. Auscher C. De Gery A. Treatment of gout with allopurinol: a studv of 1t)6 cases. Ann,l Rheutn Dis Alternatives to allopurinol 1966: 25: 627-33. 10 Rundles R W. Metabolic effects of allopurinol and In their letter to the Annals Kelsey et al state that alloxanthine. Atiti Rheu,n Dis 1966: 25: 615-2). SIR, 11 Lockard 0 Jr, Harmon C. Nolph K. Irvin W. Allergic reaction there is 'no available alternative to allopurinol with its to allopurinol with cross-reactiyity to oxypurinol. Ann Intern unique mode of action'.' There are at least two alter- Med 1976; 85: 333-5.
    [Show full text]
  • CHAPTER-IV an Improved Process for Synthesis of Febuxostat Which Is an Inhibitor of Xanthine Oxidase
    CHAPTER-IV An improved process for synthesis of Febuxostat which is an inhibitor of xanthine oxidase. INTRODUCTION : The clinical manifestations of gout, a spectrum of monoarthritic disorders characterized by crystallization of monosodium urate from supersaturated body fluids into tissues, have been well described for centuries. Although historically associated with royalty and affluent societies, increased longevity and shifts in patterns of diet and lifestyle have led to an increasing prevalence of gout worldwide, including in less-developed countries. 1,2 Attacks of acute gouty arthritis are usually treated with NSAIDs, colchicine, or corticosteroids; however, because hyperuricemia is the primary antecedent biochemical abnormality observed in patients with acute gouty arthritis, urate-lowering agents are the foundation for prevention of further attacks. Colchicine was used originally to treat rheumatic complaints, especially gout. It has toxic side effects which include gastrointestinal upset and neutropenia. 3 Colchicine poisoning has been compared to arsenic poisoning; symptoms start 2 to 5 hours after the toxic dose has been ingested and include burning in the mouth and throat, fever, vomiting, diarrhea, abdominal pain and kidney failure. 4 Hyperuricemia in humans is best defined as a serum uric acid of >6.8 mg/dL, which approaches the limit of solubility for monosodium urate in extracellular fluids. 5 Uric acid is the terminal product of a cascade of metabolic steps produced by xanthine oxidase from xanthine and hypoxanthine, which in turn are produced from purine. Uric acid is more toxic to tissues than either xanthine or hypoxanthine. Uric acid is released in hypoxic conditions. 6 In humans and higher primates, uric acid is the final oxidation (breakdown) product of purine metabolism and is excreted in urine.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]